Good to see the newly appointed gene therapy unit lead in their rare diseases division, who was supposed to be on secondment for a two year contract from King's College, has now been appointed full time with Pfizer after only 11 months into the secondment. His specialty is viral delivery of gene therapies, particularly AAV.
Might be a handy synergy if they want to expand this rare disease unit into something much bigger that goes after say HCV and HBV.
As ddRNAi proof of concept in humans is drawing near, having the gene therapy tail wind still blowing strong and not looking like easing up anytime soon is reassuring.
BLT Price at posting:
32.5¢ Sentiment: Buy Disclosure: Held
